First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease: The Dominantly Inherited Alzheimer's Network Study

TY - JOUR

T1 - First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease

T2 - The Dominantly Inherited Alzheimer's Network Study

AU - O'Connor, Antoinette

AU - Rice, Helen

AU - Barnes, Josephine

AU - Ryan, Natalie S.

AU - Liu, Kathy Y.

AU - Allegri, Ricardo Francisco

AU - Berman, Sarah

AU - Ringman, John M.

AU - Cruchaga, Carlos

AU - Farlow, Martin R.

AU - Hassenstab, Jason

AU - Lee, Jae Hong

AU - Perrin, Richard J.

AU - Xiong, Chengjie

AU - Gordon, Brian

AU - Levey, Allan I.

AU - Goate, Alison

AU - Graff-Radford, Neil

AU - Levin, Johannes

AU - Jucker, Mathias

AU - Benzinger, Tammie

AU - McDade, Eric

AU - Mori, Hiroshi

AU - Noble, James M.

AU - Schofield, Peter R.

AU - Martins, Ralph N.

AU - Salloway, Stephen

AU - Chhatwal, Jasmeer

AU - Morris, John C.

AU - Bateman, Randall

AU - Howard, Rob

AU - Reeves, Suzanne

AU - Fox, Nick C.

N1 - Funding Information: Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer Network (DIAN, U19AG032438) funded by the National Institute on Ageing (NIA),the Alzheimer’s Association (SG-20–6 90 363-DIAN), the German Centre for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Ageing, Brain Canada Foundation, and Fonds de Recherche du Québec – Santé. This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. AO'C acknowledges support from an Alzheimer’s Society clinical research training fellowship (AS-CTF18-001) and from the Rosetrees Trust (M668). NSR is supported by a University of London Chadburn Academic Clinical Lectureship. KYL is supported by the UK Medical Research Council (MRC) (MR/S021418/1). This work was supported by the NIHR UCLH/UCL Biomedical Research Centre, the Rosetrees Trust, the MRC Dementia Platform UK and the UK Dementia Research Institute at UCL which receives its funding from UK DRI (UKDRI-1001), funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. NCF has served on advisory boards or as a consultant for Biogen, Ionis, Lilly, and Roche (all payments to UCL) and has served on a data safety monitoring board for Biogen.

PY - 2023/5/1

Y1 - 2023/5/1

KW - ALZHEIMER'S DISEASE

KW - BEHAVIOURAL DISORDER

KW - COGNITION

KW - NEUROPSYCHIATRY

UR - https://www.scopus.com/pages/publications/85152602740

U2 - 10.1136/jnnp-2022-329843

DO - 10.1136/jnnp-2022-329843

M3 - Article

C2 - 36522155

AN - SCOPUS:85152602740

SN - 0022-3050

VL - 94

SP - 403

EP - 405

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

IS - 5

ER -